Business
Placing
Placing.
About this update from Optibiotix Health Plc
[{"type":"text","content":"\n \nRNS Number : 1474O OptiBiotix Health PLC 05 February 2016 \n\n5 February 2016\nOptiBiotix Health plc\n(\"OptiBiotix\" or the \"Company\")\n \nPlacing\n \nOptiBiotix Health plc (AIM: OPTI), a Life Sciences business developing products to tackle obesity, high cholesterol and diabetes is pleased to announce that it has raised £1,000,000 (before expenses) via a placing of 1,282,051 new ordinary shares (\"Placing Shares\") at a price of 78 pence per share (the \"Placing\"). \n \nThe Placing Shares have been issued to funds managed by Seneca Partners Limited (\"Seneca\"), a wealth manager and existing institutional investor in OptiBiotix. Following the Placing, Seneca's beneficial shareholding in the Company is 5,537,051 ordinary shares, representing 7.13 per cent. of the Company's issued share capital.\n \nStephen O'Hara, CEO of OptiBiotix, said: \"We are delighted that Seneca, as a major shareholder and respected wealth manager, have increased their stake in OptiBiotix. The funds will be used to further accelerate our development programmes to capitalise on the growing number of opportunities arising in the rapidly evolving microbiome space and build shareholder value.\"\n \nApplication will be made to the London Stock Exchange to admit the Placing Shares to trading on AIM. Admission of the Placing Shares is expected to occur on or around 11 February 2016. The Placing Shares will rank pari passu with the Company's existing ordinary shares.\n \nFor the purpose of the Disclosure and Transparency Rules, following the issue of the Placing Shares, the enlarged issued share capital of the Company will comprise 77,633,976 ordinary shares of 2p each. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.\n \n \n \nFor further information:\n \n\n\n\n\nOptiBiotix Health plc\n\n\nwww.optibiotix.com\n\n\n\n\nStephen O'Hara, Chief Executive\n\n\nContact via Walbrook below\n\n\n\n\n\n\n\n\n\n\n\n\nCairn Financial Advisers LLP\n\n\nTel: 020 7148 7900\n\n\n\n\nLiam Murray / Avi Robinson\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nHybridan LLP (Joint Broker)\nClaire Louise Noyce\n \n\...